The global pharmaceutical market is currently seeing a Peptide Manufacturing Expansion to address the rising need for GLP-1 therapies. CordenPharma is leading this change by increasing its operational footprint in Colorado and Europe.
This growth ensures that patients receive vital treatments for diabetes and obesity on a global scale.
CordenPharma has recently secured a 64,000 square foot facility in Boulder, Colorado. This site focuses on process development and analytical services for complex APIs. By placing this lab near existing plants, the company streamlines the path from clinical trials to commercial sales.
The company is investing €900 million to support this Peptide Manufacturing Expansion over the next three years. These funds will help build new large scale lines in both the United States and Switzerland. Consequently, the firm aims to reach over €1 billion in peptide sales by the year 2028.
This Peptide Manufacturing Expansion utilizes patented TAPS technology for faster, scalable production. It reduces solvent use by 90% and removes traditional resin needs.
TAPS creates a greener, cost-effective supply chain for CordenPharma. This award-winning innovation easily integrates peptide production into existing small-molecule assets
The primary driver for this Peptide Manufacturing Expansion is the massive surge in GLP-1 receptor agonists. Drugs like semaglutide require massive amounts of high quality API to meet patient needs. CordenPharma has already signed contracts valued at roughly €3 billion for these specific peptides.
Strategic partnerships with innovators like Viking Therapeutics highlight the importance of this growth. Their work on VK2735 depends on reliable and scalable manufacturing solutions. This alignment ensures that new metabolic disorder treatments reach the market without any logistical delays.
By 2028, the total reactor capacity in Colorado will exceed 42,000 liters. This makes it one of the largest sites for solid phase peptide synthesis in the world. Such scale is necessary for large volume API supply in late stage clinical programs.
This Peptide Manufacturing Expansion reflects a proactive response to evolving healthcare trends. As more peptide drugs enter Phase 2 and Phase 3, the industry must stay ahead of the curve. Corden Pharma is clearly positioned to remain a dominant force in the global CDMO sector.
Stay ahead of the clinical curve—the next great peptide is already in Phase 2. 💊
¹ Pharmaceutical-Technology. (n.d.). CordenPharma leases space at Flatiron Park for peptides development. Retrieved from https://www.pharmaceutical-technology.com/news/cordenpharma-flatiron-park-peptides-development/
² CordenPharma. (2024, July 16). CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe. Retrieved from https://cordenpharma.com/articles/press-release-cordenpharma-invests-900-million-euros-in-transformational-peptide-platform-expansion-in-usa-and-europe/
³ CordenPharma. (n.d.). DCAT Week 2026: Peptide Drug Substance. Retrieved from https://cordenpharma.com/learn-about-peptide-drug-substance-manufacturing-at-dcat-week-2026/
⁴ Cleanroom Technology. (2025, March 12). CordenPharma unveils ambitious €1bn investment in peptide manufacturing expansion. Retrieved from https://cleanroomtechnology.com/cordenpharma-unveils-ambitious-1bn-investment-in-peptide-manufacturing
⁵ CordenPharma. (n.d.). CordenPharma Wins 2025 CPHI Pharma Award for API Development & Innovation. Retrieved from https://cordenpharma.com/articles/cordenpharma-wins-2025-cphi-pharma-award-for-api-development-and-innovation/
⁶ CordenPharma. (2025, March 11). CordenPharma & Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables & Oral Formulations. Retrieved from https://cordenpharma.com/articles/press-release-cordenpharma-and-viking-therapeutics-sign-long-term-partnership-for-integrated-supply-of-glp-1-peptides-injectables-oral-formulations-for-vk2735/
⁷ Nauck, M. A. (2021). Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Nature Reviews Endocrinology, 17(2), 70-89.
All human research MUST be overseen by a medical professional.
